Douglas Einstein, MD
Radiation Oncology · Kettering, OHNPI 1275563413
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 19 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by Bristol Myers Squibb at 25.2% of the total. Reporting peaked in 2024 at $139 and has fallen 80.1% since, to $28 in 2025.
Across 19 payments — averaging $24.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bristol Myers Squibb$119
- Johnson & Johnson$82
- Pharmacyclics LLC, An Abbvie Company$77
- Springworks Therapeutics, Inc.$46
- AbbVie$34
- Foundation Medicine, Inc.$33
- plus $81 from 4 others
What the payments were for
- Food & beverage$471100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bristol Myers Squibb | 7 | $119 |
| Johnson & Johnson | 1 | $82 |
| Pharmacyclics LLC, An Abbvie Company | 3 | $77 |
| Springworks Therapeutics, Inc. | 2 | $46 |
| AbbVie | 1 | $34 |
| Foundation Medicine, Inc. | 1 | $33 |
| Progenics Pharmaceuticals, Inc. | 1 | $28 |
| Medtronic | 1 | $24 |
| Novartis | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
How this compares
$471 in reported general payments places this provider in the 55th percentile of 255 radiation oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Sucralfate | 37 | $625 |
| Dexamethasone | 54 | $368 |
| Tamsulosin Hcl | 11 | $22 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Kettering
- Anthony ParavatiKettering$24K
- Steven KurtzmanGarfield Heights$833K
- Joshua PalmerColumbus$123K
- Norleena PoynterSandusky$90K
- Daniel SprattCleveland$86K
- Shlomo KoyfmanCleveland$72K
- Gerald SokolCleveland$61K
- Peter FriedFairfield$45K
- Rahul TendulkarCleveland$26K
- Sujith BaligaColumbus$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.